Pathogenesis of non-HLA antibodies in solid organ transplantation: Where do we stand?

Human Immunology

Volumn 77, Issue 11, 2016, Pages 1055-1062

  Delville, Marianne ^a,b   Charreau, Béatrice ^a,c   Rabant, Marion ^a   Legendre, Christophe ^a,b,d   Anglicheau, Dany ^a,b,d  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b Paris Diderot Sorbonne Cite University   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Anti endothelial cell antibody; Endothelial injury; Humoral rejection; Transplantation

Indexed keywords

ANGIOTENSIN II TYPE 1 RECEPTOR ANTIBODY; ANTIBODY; COLLAGEN ANTIBODY; ENDOTHELIAL CELL ANTIBODY; ENDOTHELIN 1 TYPE A RECEPTOR ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I RELATED CHAIN ANTIBODY; MYOSIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VIMENTIN ANTIBODY; ALLOANTIBODY; ANTI-ENDOTHELIAL CELL ANTIBODY; AUTOANTIBODY; HLA ANTIGEN;

ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; CLINICAL PRACTICE; GRAFT REJECTION; HUMAN; LUNG TRANSPLANTATION; NONHUMAN; ORGAN TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; HISTOCOMPATIBILITY; HUMORAL IMMUNITY; IMMUNOLOGY; KIDNEY TRANSPLANTATION; METABOLISM;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; AUTOANTIBODIES; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNITY, HUMORAL; ISOANTIBODIES; KIDNEY TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 84973883590     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2016.05.021     Document Type: Review

References (76)

1. [1] Haas, M., Sis, B., Racusen, L.C., Solez, K., Glotz, D., Colvin, R.B., et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am. J. Transplant. 14 (2014), 272–283.
2. [2] Kissmeyer-Nielsen, F., Olsen, S., Petersen, V.P., Fjeldborg, O., Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 2 (1966), 662–665.
3. [3] Halloran, P.F., Wadgymar, A., Ritchie, S., Falk, J., Solez, K., Srinivasa, N.S., The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 49 (1990), 85–91.
4. [4] Halloran, P.F., Schlaut, J., Solez, K., Srinivasa, N.S., The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 53 (1992), 550–555.
5. [5] Feucht, H.E., Felber, E., Gokel, M.J., Hillebrand, G., Nattermann, U., Brockmeyer, C., et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin. Exp. Immunol. 86 (1991), 464–470.
6. [6] Regele, H., Bohmig, G.A., Habicht, A., Gollowitzer, D., Schillinger, M., Rockenschaub, S., et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J. Am. Soc. Nephrol. 13 (2002), 2371–2380.
7. [7] Einecke, G., Sis, B., Reeve, J., Mengel, M., Campbell, P.M., Hidalgo, L.G., et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am. J. Transplant. 9 (2009), 2520–2531.
8. [8] Opelz, G., Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 365 (2005), 1570–1576.
9. [9] Jackson, A.M., Kuperman, M.B., Montgomery, R.A., Multiple hyperacute rejections in the absence of detectable complement activation in a patient with endothelial cell reactive antibody. Am. J. Transplant. 12 (2012), 1643–1649.
10. [10] Jordan, S.C., Yap, H.K., Sakai, R.S., Alfonso, P., Fitchman, M., Hyperacute allograft rejection mediated by anti-vascular endothelial cell antibodies with a negative monocyte crossmatch. Transplantation 46 (1988), 585–587.
11. [11] Harmer, A.W., Haskard, D., Koffman, C.G., Welsh, K.I., Novel antibodies associated with unexplained loss of renal allografts. Transpl. Int. 3 (1990), 66–69.
12. [12] Sumitran-Karuppan, S., Tyden, G., Reinholt, F., Berg, U., Moller, E., Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells. Transpl. Immunol. 5 (1997), 321–327.
13. [13] Paul, L.C., Baldwin, W.M. 3rd, van Es, L.A., Vascular endothelial alloantigens in renal transplantation. Transplantation 40 (1985), 117–123.
14. [14] Lefaucheur, C., Loupy, A., Hill, G.S., Andrade, J., Nochy, D., Antoine, C., et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J. Am. Soc. Nephrol. 21 (2010), 1398–1406.
15. [15] Amico, P., Honger, G., Bielmann, D., Lutz, D., Garzoni, D., Steiger, J., et al. Incidence and prediction of early antibody-mediated rejection due to non-human leukocyte antigen-antibodies. Transplantation 85 (2008), 1557–1563.
16. [16] Colvin, R.B., Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J. Am. Soc. Nephrol. 18 (2007), 1046–1056.
17. [17] Li, L., Wadia, P., Chen, R., Kambham, N., Naesens, M., Sigdel, T.K., et al. Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and “antibodyome” measures. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 4148–4153.
18. [18] Spanel-Borowski, K., Bein, G., Different microvascular endothelial cell phenotypes exhibit different class I and II antigens under interferon-gamma. In Vitro Cell. Dev. Biol. Anim. 29A (1993), 601–602.
19. [19] Canet, E., Devalliere, J., Gerard, N., Karam, G., Giral, M., Charreau, B., et al. Profiling posttransplant circulating antibodies in kidney transplantation using donor endothelial cells. Transplantation 93 (2012), 257–264.
20. [20] Vermehren, D., Sumitran-Holgersson, S., Isolation of precursor endothelial cells from peripheral blood for donor-specific crossmatching before organ transplantation. Transplantation 74 (2002), 1479–1486.
21. [21] Breimer, M.E., Rydberg, L., Jackson, A.M., Lucas, D.P., Zachary, A.A., Melancon, J.K., et al. Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation 87 (2009), 549–556.
22. [22] Jackson, A.M., Lucas, D.P., Badders, J.L., A flow cytometric crossmatch test using endothelial precursor cells isolated from peripheral blood. Methods Mol. Biol. 1034 (2013), 319–329.
23. [23] Xavier, P., Aires, P., Sampaio, S., Mendes, C., Monteiro, M., Alves, H., et al. XM-ONE detection of endothelium cell antibodies identifies a subgroup of HLA-antibody negative patients undergoing acute rejection. Transplant. Proc. 43 (2011), 91–94.
24. [24] Sun, Q., Cheng, Z., Cheng, D., Chen, J., Ji, S., Wen, J., et al. De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection. Kidney Int. 79 (2011), 655–662.
25. [25] Kalil, J., Guilherme, L., Neumann, J., Rosales, C., Marin, M., Saldanha, L., et al. Humoral rejection in two HLA identical living related donor kidney transplants. Transplant. Proc. 21 (1989), 711–713.
26. [26] Sumitran-Holgersson, S., Wilczek, H.E., Holgersson, J., Soderstrom, K., Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 74 (2002), 268–277.
27. [27] Hankey, K.G., Drachenberg, C.B., Papadimitriou, J.C., Klassen, D.K., Philosophe, B., Bartlett, S.T., et al. MIC expression in renal and pancreatic allografts. Transplantation 73 (2002), 304–306.
28. [28] Quiroga, I., Salio, M., Koo, D.D., Cerundolo, L., Shepherd, D., Cerundolo, V., et al. Expression of MHC class I-related Chain B (MICB) molecules on renal transplant biopsies. Transplantation 81 (2006), 1196–1203.
29. [29] Mizutani, K., Terasaki, P., Hamdani, E., Esquenazi, V., Rosen, A., Miller, J., et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am. J. Transplant. 7 (2007), 1027–1031.
30. [30] Suarez-Alvarez, B., Lopez-Vazquez, A., Gonzalez, M.Z., Fdez-Morera, J.L., Diaz-Molina, B., Blanco-Gelaz, M.A., et al. The relationship of anti-MICA antibodies and MICA expression with heart allograft rejection. Am. J. Transplant. 7 (2007), 1842–1848.
31. [31] Panigrahi, A., Gupta, N., Siddiqui, J.A., Margoob, A., Bhowmik, D., Guleria, S., et al. Monitoring of anti-HLA and anti-Major histocompatibility complex class I related chain A antibodies in living related renal donor transplantation. Transplant. Proc. 39 (2007), 759–760.
32. [32] Terasaki, P.I., Ozawa, M., Castro, R., Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am. J. Transplant. 7 (2007), 408–415.
33. [33] Zou, Y., Stastny, P., Susal, C., Dohler, B., Opelz, G., Antibodies against MICA antigens and kidney-transplant rejection. N. Engl. J. Med. 357 (2007), 1293–1300.
34. [34] Zou, Y., Stastny, P., Role of MICA in the immune response to transplants. Tissue Antigens 76 (2010), 171–176.
35. [35] Mizutani, K., Terasaki, P.I., Shih, R.N., Pei, R., Ozawa, M., Lee, J., Frequency of MIC antibody in rejected renal transplant patients without HLA antibody. Hum. Immunol. 67 (2006), 223–229.
36. [36] Tonnerre, P., Gerard, N., Chatelais, M., Poli, C., Allard, S., Cury, S., et al. MICA variant promotes allosensitization after kidney transplantation. J. Am. Soc. Nephrol. 24 (2013), 954–966.
37. [37] Dragun, D., Muller, D.N., Brasen, J.H., Fritsche, L., Nieminen-Kelha, M., Dechend, R., et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N. Engl. J. Med. 352 (2005), 558–569.
38. [38] Reinsmoen, N.L., Lai, C.H., Heidecke, H., Haas, M., Cao, K., Ong, G., et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 90 (2010), 1473–1477.
39. [39] Giral, M., Foucher, Y., Dufay, A., Van Huyen, J.P., Renaudin, K., Moreau, A., et al. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am. J. Transplant. 13 (2013), 2567–2576.
40. [40] Taniguchi, M., Rebellato, L.M., Cai, J., Hopfield, J., Briley, K.P., Haisch, C.E., et al. Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. Am. J. Transplant. 13 (2013), 2577–2589.
41. [41] Hiemann, N.E., Meyer, R., Wellnhofer, E., Schoenemann, C., Heidecke, H., Lachmann, N., et al. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation 94 (2012), 919–924.
42. [42] Banasik, M., Boratynska, M., Koscielska-Kasprzak, K., Krajewska, M., Mazanowska, O., Kaminska, D., et al. The impact of non-HLA antibodies directed against endothelin-1 type A receptors (ETAR) on early renal transplant outcomes. Transpl. Immunol. 30 (2014), 24–29.
43. [43] Porcheray, F., DeVito, J., Yeap, B.Y., Xue, L., Dargon, I., Paine, R., et al. Chronic humoral rejection of human kidney allografts associates with broad autoantibody responses. Transplantation 89 (2010), 1239–1246.
44. [44] Porcheray, F., Fraser, J.W., Gao, B., McColl, A., DeVito, J., Dargon, I., et al. Polyreactive antibodies developing amidst humoral rejection of human kidney grafts bind apoptotic cells and activate complement. Am. J. Transplant. 13 (2013), 2590–2600.
45. [45] Ikematsu, H., Kasaian, M.T., Schettino, E.W., Casali, P., Structural analysis of the VH-D-JH segments of human polyreactive IgG mAb. Evidence for somatic selection. J. Immunol. 151 (1993), 3604–3616.
46. [46] Gao, B., Rong, C., Porcheray, F., Moore, C., Girouard, T.C., Saidman, S.L., et al. Evidence to support a contribution of polyreactive antibodies to HLA serum reactivity. Transplantation 100 (2016), 217–226.
47. [47] Soulez, M., Pilon, E.A., Dieude, M., Cardinal, H., Brassard, N., Qi, S., et al. The perlecan fragment LG3 is a novel regulator of obliterative remodeling associated with allograft vascular rejection. Circ. Res. 110 (2012), 94–104.
48. [48] O'Riordan, E., Orlova, T.N., Mendelev, N., Patschan, D., Kemp, R., Chander, P.N., et al. Urinary proteomic analysis of chronic allograft nephropathy. Proteomics Clin. Appl. 2 (2008), 1025–1035.
49. [49] Cardinal, H., Dieude, M., Brassard, N., Qi, S., Patey, N., Soulez, M., et al. Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury. Am. J. Transplant. 13 (2013), 861–874.
50. [50] Jurcevic, S., Ainsworth, M.E., Pomerance, A., Smith, J.D., Robinson, D.R., Dunn, M.J., et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 71 (2001), 886–892.
51. [51] Mahesh, B., Leong, H.S., Nair, K.S., McCormack, A., Sarathchandra, P., Rose, M.L., Autoimmunity to vimentin potentiates graft vasculopathy in murine cardiac allografts. Transplantation 90 (2010), 4–13.
52. [52] Mahesh, B., Leong, H.S., McCormack, A., Sarathchandra, P., Holder, A., Rose, M.L., Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. Am. J. Pathol. 170 (2007), 1415–1427.
53. [53] Warraich, R.S., Pomerance, A., Stanley, A., Banner, N.R., Dunn, M.J., Yacoub, M.H., Cardiac myosin autoantibodies and acute rejection after heart transplantation in patients with dilated cardiomyopathy. Transplantation 69 (2000), 1609–1617.
54. [54] Burlingham, W.J., Love, R.B., Jankowska-Gan, E., Haynes, L.D., Xu, Q., Bobadilla, J.L., et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J. Clin. Invest. 117 (2007), 3498–3506.
55. [55] Goers, T.A., Ramachandran, S., Aloush, A., Trulock, E., Patterson, G.A., Mohanakumar, T., De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J. Immunol. 180 (2008), 4487–4494.
56. [56] Fukami, N., Ramachandran, S., Saini, D., Walter, M., Chapman, W., Patterson, G.A., et al. Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J. Immunol. 182 (2009), 309–318.
57. [57] Saini, D., Weber, J., Ramachandran, S., Phelan, D., Tiriveedhi, V., Liu, M., et al. Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J. Heart Lung Transplant. 30 (2011), 624–631.
58. [58] Angaswamy, N., Tiriveedhi, V., Sarma, N.J., Subramanian, V., Klein, C., Wellen, J., et al. Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection. Hum. Immunol. 74 (2013), 1478–1485.
59. [59] Dinavahi, R., George, A., Tretin, A., Akalin, E., Ames, S., Bromberg, J.S., et al. Antibodies reactive to non-HLA antigens in transplant glomerulopathy. J. Am. Soc. Nephrol. 22 (2011), 1168–1178.
60. [60] Halloran, P.F., Transplantation: Autoantibodies-epiphenomena or biological clues. Nat. Rev. Nephrol. 9 (2013), 705–706.
61. [61] Sutherland, S.M., Li, L., Sigdel, T.K., Wadia, P.P., Miklos, D.B., Butte, A.J., et al. Protein microarrays identify antibodies to protein kinase Czeta that are associated with a greater risk of allograft loss in pediatric renal transplant recipients. Kidney Int. 76 (2009), 1277–1283.
62. [62] Le Roux, S., Devys, A., Girard, C., Harb, J., Hourmant, M., Biomarkers for the diagnosis of the stable kidney transplant and chronic transplant injury using the ProtoArray(R) technology. Transplant. Proc. 42 (2010), 3475–3481.
63. [63] Sigdel, T.K., Li, L., Tran, T.Q., Khatri, P., Naesens, M., Sansanwal, P., et al. Non-HLA antibodies to immunogenic epitopes predict the evolution of chronic renal allograft injury. J. Am. Soc. Nephrol. 23 (2012), 750–763.
64. [64] Jackson, A.M., Sigdel, T.K., Delville, M., Hsieh, S.C., Dai, H., Bagnasco, S., et al. Endothelial cell antibodies associated with novel targets and increased rejection. J. Am. Soc. Nephrol. 26 (2015), 1161–1171.
65. [65] Collins, A.B., Schneeberger, E.E., Pascual, M.A., Saidman, S.L., Williams, W.W., Tolkoff-Rubin, N., et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J. Am. Soc. Nephrol. 10 (1999), 2208–2214.
66. [66] Dragun, D., Catar, R., Philippe, A., Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance. Curr. Opin. Organ Transplant. 18 (2013), 430–435.
67. [67] Scornik, J.C., Guerra, G., Schold, J.D., Srinivas, T.R., Dragun, D., Meier-Kriesche, H.U., Value of posttransplant antibody tests in the evaluation of patients with renal graft dysfunction. Am. J. Transplant. 7 (2007), 1808–1814.
68. [68] Yuan, F.F., Watson, N., Sullivan, J.S., Biffin, S., Moses, J., Geczy, A.F., et al. Association of Fc gamma receptor IIA polymorphisms with acute renal-allograft rejection. Transplantation 78 (2004), 766–769.
69. [69] Resch, T., Fabritius, C., Ebner, S., Ritschl, P., Kotsch, K., The role of natural killer cells in humoral rejection. Transplantation 99 (2015), 1335–1340.
70. [70] Crespo, M., Yelamos, J., Redondo, D., Muntasell, A., Perez-Saez, M.J., Lopez-Montanes, M., et al. Circulating NK-cell subsets in renal allograft recipients with anti-HLA donor-specific antibodies. Am. J. Transplant. 15 (2015), 806–814.
71. [71] Vidarsson, G., Dekkers, G., Rispens, T., IgG subclasses and allotypes: from structure to effector functions. Front. Immunol., 5, 2014, 520.
72. [72] Le Bas-Bernardet, S., Coupel, S., Chauveau, A., Soulillou, J.P., Charreau, B., Vascular endothelial cells evade apoptosis triggered by human leukocyte antigen-DR ligation mediated by allospecific antibodies. Transplantation 78 (2004), 1729–1739.
73. [73] Zhang, X., Rozengurt, E., Reed, E.F., HLA class I molecules partner with integrin beta4 to stimulate endothelial cell proliferation and migration. Sci. Signal., 3, 2010, ra85.
74. [74] Coupel, S., Leboeuf, F., Boulday, G., Soulillou, J.P., Charreau, B., RhoA activation mediates phosphatidylinositol 3-kinase-dependent proliferation of human vascular endothelial cells: an alloimmune mechanism of chronic allograft nephropathy. J. Am. Soc. Nephrol. 15 (2004), 2429–2439.
75. [75] Le Bas-Bernardet, S., Hourmant, M., Coupel, S., Bignon, J.D., Soulillou, J.P., Charreau, B., Non-HLA-type endothelial cell reactive alloantibodies in pre-transplant sera of kidney recipients trigger apoptosis. Am. J. Transplant. 3 (2003), 167–177.
76. [76] Regele, H., Non-HLA antibodies in kidney allograft rejection: convincing concept in need of further evidence. Kidney Int. 79 (2011), 583–586.